BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 1.90B |
| Revenue (ttm) | 53.52M |
| Net Income (ttm) | -124.94M |
| Shares Out | 176.52M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $10.78 |
| Previous Close | $10.47 |
| Change ($) | 0.31 |
| Change (%) | 2.96% |
| Day's Open | 10.88 |
| Day's Range | 10.29 - 11.09 |
| Day's Volume | 4,942,442 |
| 52-Week Range | 1.58 - 12.90 |
The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralst...
For investors and media only
The company's fourth-quarter earnings report did not pass muster.
BioCryst (BCRX) delivered earnings and revenue surprises of -36.00% and -72.72%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020...
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 202...
In less than several weeks, BioCryst Pharmaceuticals (NASDAQ: BCRX) shares have advanced from $7.2 above $12, and the current price stands around $10.2. According to the latest news, the FDA a...
Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical...
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicate...
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a su...
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares, which had been locked in a trading range since the start of January, broke out of the range Monday and rallied strongly, only to pull back...
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors g...
BioCryst Pharmaceuticals surged 39% to a five-year high on Monday as Reddit investors declared a "BioWar" against short-sellers betting against the stock. The move followed a post on the r/Wal...
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science ...
RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has...
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors g...
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healt...
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.
Investors were disappointed by the biotech's COVID-19 clinical trial results.
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum ant...
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin rec...
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U...
—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care —
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Sum...
BioCryst received FDA approval for Orladeyo last week. The company quickly moved to raise cash and remove the financing overhang.
BioCryst (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has received a price target increase from $13 to $14 by H.C. Wainwright.
The recent FDA approval of Orladeyo (Berotralstat) has completely de-risked BioCryst's future. Orladeyo has the ability to be a "blockbuster drug" and we are of the opinion that it very much h...
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, L...
—Data presented at the 62nd American Society of Hematology Annual Meeting—
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutr...
BioCryst Pharma (BCRX) news for Friday concerning approval from the FDA for one of its drugs has BCRX stock soaring higher. The post BioCryst Pharma News: Why BCRX Stock Is Soaring Today appea...
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
—Significant and sustained reduction in HAE attacks—
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors g...
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the journal Allergy has published data from the APeX-J trial, a ra...
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual Health...
—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— —Data presented at 2020 Annual Scientific Meeting of the American College of ...
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will...
BioCryst recently reported additional results of BCX9930 in PNH patients naïve to C5 inhibitors. The results were not perfect but seem good enough to support further development.
On November 5, BioCryst Pharmaceuticals reported results for the 3rd quarter of 2020. BioCryst has a flood of catalysts before it in the coming weeks: Berotralstat approval in USA, Japan, and ...
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2020 Results - Earnings Call Transcript
BioCryst (BCRX) delivered earnings and revenue surprises of -4.00% and 41.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; ... [Read more...]
| Industry Biotechnology | IPO Date Mar 3, 1994 |
| CEO Jon Stonehouse | Employees 140 |
| Stock Exchange NASDAQ | Ticker Symbol BCRX |
Financial Performance
In 2019, BCRX's revenue was $48.84 million, an increase of 136.45% compared to the previous year's $20.65 million. Losses were -$108.90 million, 7.55% more than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 13.50, which is an increase of 25.23% from the latest price.